DDX43 and chronic myelogenous leukemia, BCR-ABL1 positive: DDX43 has been identified as being overexpressed in a range of solid tumors including those affecting the salivary gland, colon, brain, lung, and prostate, as well as in hematologic malignancies like chronic myeloid leukemia and multiple myeloma [22–29].